Tonix Pharmaceuticals (NASDAQ:TNXP) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP) in a report issued on Monday. The firm issued a sell rating on the stock.

Separately, Alliance Global Partners increased their target price on shares of Tonix Pharmaceuticals from $6.00 to $11.00 and gave the stock a “buy” rating in a research note on Monday, July 22nd.

Tonix Pharmaceuticals Stock Down 8.1 %

TNXP stock opened at $0.15 on Monday. The company’s 50 day moving average is $0.18 and its two-hundred day moving average is $1.84. Tonix Pharmaceuticals has a twelve month low of $0.12 and a twelve month high of $22.14. The company has a current ratio of 1.15, a quick ratio of 0.72 and a debt-to-equity ratio of 0.13. The stock has a market cap of $21.19 million, a P/E ratio of 0.00 and a beta of 2.08.

Tonix Pharmaceuticals (NASDAQ:TNXP) last issued its quarterly earnings data on Friday, August 16th. The company reported ($19.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($9.91) by ($9.37). The firm had revenue of $2.21 million for the quarter, compared to analysts’ expectations of $3.50 million. Tonix Pharmaceuticals had a negative return on equity of 158.27% and a negative net margin of 1,196.11%. Research analysts expect that Tonix Pharmaceuticals will post -18 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Tonix Pharmaceuticals

A hedge fund recently raised its stake in Tonix Pharmaceuticals stock. Acadian Asset Management LLC increased its stake in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) by 260.6% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 335,373 shares of the company’s stock after purchasing an additional 242,358 shares during the quarter. Acadian Asset Management LLC owned 0.40% of Tonix Pharmaceuticals worth $61,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 82.26% of the company’s stock.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.